

Fig. S1. Design of the ESTEEM 1 and 2 studies. *Doses of apremilast were titrated during the first week of administration and at Week 16 when placebo patients were switched to apremilast. §PASI-75 (ESTEEM 1) or PASI-50 (ESTEEM 2). ‡In ESTEEM 1, patients were switched to apremilast at the time of loss of PASI-75, but no later than Week 52. In ESTEEM 2, patients were switched to apremilast at time of loss of effect, defined as time of loss of 50% of the PASI improvement obtained at Week 32 compared to baseline, but no later than Week 52.‖Patients initially on placebo or randomized to apremilast 30 mg BID who did not attain a PASI-75 (ESTEEM 1) or PASI-50 (ESTEEM 2) were able to add topicals and/or UVB at Week 32 at the discretion of the investigator.



Fig. S2. Correlations between mean changes from baseline in VAS scores for PgAPDA and pruritus or skin discomfort/pain at Week 16 and Week 32 in ESTEEM 1 (A) and ESTEEM 2 (B)

Table SI. *Baseline demographic and disease characteristics (all randomized patients)*

	ESTEEM 1		ESTEEM 2	
	Placebo *n* = 282	Apremilast 30 mg BID *n* = 562	Placebo *n* = 137	Apremilast 30 mg BID *n* = 274
Age, years, mean (SD)	46.5 (12.7)	45.8 (13.1)	45.7 (13.4)	45.3 (13.1)
Male, *n* (%)	194 (68.8)	379 (67.4)	100 (73.0)	176 (64.2)
White, *n* (%)	250 (88.7)	507 (90.2)	128 (93.4)	250 (91.2)
Body mass index, kg/m^2, mean (SD)	31.3 (7.4)	31.2 (6.7)	30.7 (7.1)	30.9 (6.7)
Duration of plaque psoriasis, years, mean (SD)	18.7 (12.4)	19.8 (13.0)	18.7 (12.1)	17.9 (11.4)
Psoriasis Area and Severity Index score, mean (SD)	19.4 (7.4)	18.7 (7.2)	20.0 (8.0)	18.9 (7.1)
Psoriasis Area and Severity Index score > 20, *n* (%)	87 (30.9)	158 (28.1)	49 (35.8)	81 (29.6)
Body surface area, %, mean (SD)	25.3 (14.6)	24.4 (14.7)	27.6 (15.8)	25.5 (15.4)
Body surface area > 20%, *n* (%)	149 (52.8)	266 (47.3)	80 (58.4)	143 (52.2)
Static Physician Global Assessment of 4 (severe), *n* (%)	89 (31.6)	161 (28.6)	49 (35.8)	75 (27.4)
Pruritus (0–100 mm VAS), mean (SD)	65.2 (24.8)	66.2 (25.5)	65.0 (26.0)	67.8 (25.2)
Skin discomfort/pain (0–100 mm VAS), mean (SD)	57.1 (29.7)	58.1 (29.3)	56.9 (28.9)	58.9 (28.9)
Patient global assessment of psoriasis disease activity VAS (0–100 mm), mean (SD)	49.6 (26.95)	50.1 (27.62)	50.4 (28.22)	52.4 (27.40)
Dermatology Life Quality Index score, mean (SD)	12.2 (6.7)	12.7 (7.1)	12.8 (7.0)	12.6 (7.2)
Prior conventional systemic therapy, *n* (%)	102 (36.2)	212 (37.7)	53 (38.7)	106 (38.7)
Prior biologic therapy, *n* (%)	80 (28.4)	162 (28.8)	44 (32.1)	92 (33.6)

The *n* reflects the number of randomized patients; actual number of patients available for each parameter may vary. Pruritus and skin discomfort/pain visual analog scale (VAS) (mm) and patient global assessment of psoriasis disease activity VAS values were based on patients with a non-zero baseline value (ESTEEM 1 and 2, placebo *n* = 277, *n* = 133, apremilast 30 mg BID, *n* = 559, *n* = 268, respectively).